Skip to main content
. 2019 Feb 15;9(1):93–109.

Figure 2.

Figure 2

Anti-ELTD1 Ab treatment is more effective in restoring tumor-associated vascularity to normal, compared to anti-VEGFR2 Ab treatment. Representative T2-weighted MR images from G55 glioma-bearing mice either IgG- (A), anti-ELTD1 Ab- (C), or anti-VEGFR2 Ab-treated (E). Representative MR perfusion maps from G55 tumors either IgG- (B), anti-ELTD1-Ab- (D), or anti-VEGFR2-Ab-treated (F). (G) Normalized (against muscle tissue) tumor rCBF differences (late to early time periods) for tumor growth measured from MR perfusion images obtained from treated G55 tumors. n = 5 for IgG, n = 12 for anri-ELTD1 Ab, and n = 7 for anti-VEGFR2-Ab-treated mice. Anti-ELTD1 Ab treatement was found to significantly reduce rCBF differences when compared to IgG (P < 0.001) or anti-VEGFR2 Ab treatment (P < 0.01). Mean ± SD.